COSMO PHARMACEUTICALS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.3 CHF | +1.21% |
|
+6.81% | +47.94% |
| Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day | |
| Mar. 20 | Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024 | CI |
| Sales 2023 | 96.72M 103M 94.63M | Sales 2024 * | 262M 280M 256M | Capitalization | 1.24B 1.32B 1.21B |
|---|---|---|---|---|---|
| Net income 2023 | 1M 1.07M 978K | Net income 2024 * | 111M 119M 109M | EV / Sales 2023 | 8.6 x |
| Net cash position 2023 | 48.44M 51.81M 47.39M | Net cash position 2024 * | 110M 118M 108M | EV / Sales 2024 * | 4.31 x |
| P/E ratio 2023 |
771
x | P/E ratio 2024 * |
10.6
x | Employees | 319 |
| Yield 2023 |
3.65% | Yield 2024 * |
2.72% | Free-Float | 44.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cosmo Pharmaceuticals N.V.
More recommendations
More press releases
More news
| 1 day | +1.21% | ||
| 1 week | +6.81% | ||
| Current month | +5.61% | ||
| 1 month | +13.92% | ||
| 3 months | +22.04% | ||
| 6 months | +115.45% | ||
| Current year | +47.94% |
1 week
69.80
76.00
1 month
65.0076.00
Current year
51.2076.00
1 year
33.7076.00
3 years
33.7092.80
5 years
33.70103.00
10 years
33.70193.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 05-12-31 | |
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 16-05-31 |
| Chief Tech/Sci/R&D Officer | 54 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David W Maris
BRD | Director/Board Member | 57 | 21-05-27 |
| Founder | 69 | 96-12-31 | |
| Director/Board Member | 64 | 05-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 773 M€ | -.--% | - | |
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 75.3 | +1.21% | 17,185 |
| 24-04-23 | 74.4 | +1.36% | 26,912 |
| 24-04-22 | 73.4 | +2.80% | 21,855 |
| 24-04-19 | 71.4 | +0.28% | 18,682 |
| 24-04-18 | 71.2 | +0.99% | 15,046 |
Delayed Quote Swiss Exchange, April 24, 2024 at 11:31 am EDT
More quotes
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellersâ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Sector
Pharmaceuticals
Calendar
2024-05-23
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
77.1
EUR
Average target price
95.63
EUR
Spread / Average Target
+24.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +47.94% | 1.31B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- COPN Stock
